A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation
A Randomized, Phase II, Open Label Study to Compare Twice Daily and Once Daily Potent Antiretroviral Therapy and to Compare Self-Administered Therapy and Therapy Administered Under Direct Observation
調査の概要
詳細な説明
While many factors contribute to the success or failure of antiretroviral therapy for HIV, among the most important are factors that influence adherence to a treatment regimen, such as duration of therapy, dosing frequency, pill burden, side effects, and patient behaviors. Inconsistent adherence or nonadherence to antiretroviral therapy can result in suboptimal drug exposure. Suboptimal drug exposure can, in turn, impact short- and long-term patient outcomes by increasing the likelihood of drug resistant HIV mutants and subsequent virologic and clinical failure. It is therefore essential to design treatment regimens that promote long-term adherence to potent antiretroviral therapy. This study will evaluate the relative contribution of reduced-frequency dosing and directly observed therapy on the magnitude and durability of virologic suppression in patients treated with potent antiretroviral therapy.
Patients will be randomly assigned to one of three study arms. Arms A, B, and C receive the same daily dosage of lopinavir/ritonavir (LPV/r), emtricitabine (FTC), and stavudine extended release (d4T XR) or tenofovir DF (TDF). In Arm A, drugs are self-administered for 48 weeks; LPV/r is taken twice daily and FTC and d4T XR or TDF once daily. In Arm B, all drugs are self-administered once daily for 48 weeks. In Arm C, drugs are taken once a day under directly observed therapy during Weeks 0-24, and then by self-administration during Weeks 25-48. Adherence to the regimen is measured using an electronic drug monitoring system. Viral load, CD4 and CD8 T cell responses, population pharmacokinetics, and quality of life indicators are measured throughout the study. The tolerability and safety of the treatment regimens are also monitored.
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
California
-
Los Angeles、California、アメリカ、90033-1079
- USC CRS
-
Sacramento、California、アメリカ
- Univ. of California Davis Med. Ctr., ACTU
-
San Diego、California、アメリカ、92103
- Ucsd, Avrc Crs
-
-
Colorado
-
Aurora、Colorado、アメリカ、80262
- University of Colorado Hospital CRS
-
-
Florida
-
Miami、Florida、アメリカ、33136
- Univ. of Miami AIDS CRS
-
-
Hawaii
-
Honolulu、Hawaii、アメリカ、96816-2396
- Univ. of Hawaii at Manoa, Leahi Hosp.
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46202-5250
- Indiana Univ. School of Medicine, Infectious Disease Research Clinic
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21287
- Johns Hopkins Adult AIDS CRS
-
Baltimore、Maryland、アメリカ、21201
- IHV Baltimore Treatment CRS
-
-
Massachusetts
-
Fall River、Massachusetts、アメリカ
- SSTAR, Family Healthcare Ctr.
-
-
Minnesota
-
Minneapolis、Minnesota、アメリカ、55455-0392
- University of Minnesota, ACTU
-
-
New York
-
New York、New York、アメリカ、10003
- Beth Israel Med. Ctr., ACTU
-
New York、New York、アメリカ、10016
- NY Univ. HIV/AIDS CRS
-
Rochester、New York、アメリカ、14215
- Univ. of Rochester ACTG CRS
-
Rochester、New York、アメリカ、14642-0001
- AIDS Care CRS
-
Rochester、New York、アメリカ、14642-0001
- McCree McCuller Wellness Ctr. at the Connection, Infectious Disease Unit
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27514
- Unc Aids Crs
-
Greensboro、North Carolina、アメリカ、27401-1004
- Regional Center for Infectious Disease, Wendover Medical Center CRS
-
Raleigh、North Carolina、アメリカ
- Wake County Health and Human Services CRS
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45267-0405
- Univ. of Cincinnati CRS
-
Cleveland、Ohio、アメリカ、44109-1998
- MetroHealth CRS
-
Columbus、Ohio、アメリカ
- The Ohio State Univ. AIDS CRS
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- Hosp. of the Univ. of Pennsylvania CRS
-
Pittsburgh、Pennsylvania、アメリカ、15213-2582
- Pitt CRS
-
-
Rhode Island
-
Providence、Rhode Island、アメリカ、02906
- The Miriam Hosp. ACTG CRS
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37203
- Vanderbilt Therapeutics CRS
-
-
Washington
-
Seattle、Washington、アメリカ、98104
- University of Washington AIDS CRS
-
-
-
-
-
San Juan、プエルトリコ、00936-5067
- Puerto Rico-AIDS CRS
-
-
-
-
Gauteng
-
Johannesburg、Gauteng、南アフリカ
- Wits HIV CRS
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria
- HIV infection
- Age 13 years or older and have written consent of guardian if under 18
- Weigh at least 88 pounds
- Viral load of 2000 copies/ml or more within 90 days before study entry
- Have not taken anti-HIV drugs for more than 7 days
- Agree to use acceptable methods of contraception during the study and for 1 month after stopping the study drugs
Exclusion Criteria
- Pregnant or breastfeeding
- In jail
- Sensitive or allergic to any part of the study drugs
- Treated with acute systemic therapy for a serious infection or other serious medical illness within 7 days prior to study entry, unless the participant has completed 7 days of therapy and is clinically stable
- Recent serious illness, including pancreatitis or peripheral neuropathy
- Alcohol or illicit drug abuse
- Taken any of the following within 14 days before study entry: investigational drugs, anti-HIV vaccines, drugs that may cause pancreatitis or peripheral neuropathy, or drugs that are associated with CYP3A
- Treated for cancer (not including minimal Kaposi's sarcoma) within 30 days before study entry
- History of mental illness that might interfere with the study
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
協力者と研究者
捜査官
- スタディチェア:Donna Mildvan, MD、Beth Israel Medical Center
- スタディチェア:Charles Flexner, MD、Johns Hopkins University Hospital
出版物と役立つリンク
一般刊行物
- Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000 Jul 4;133(1):21-30. doi: 10.7326/0003-4819-133-1-200007040-00004. Erratum In: Ann Intern Med 2002 Feb 5;136(3):253.
- Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, Christian J, Maldonado T, Duran D, Kaplan AH, Wenger NS. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001 May 15;134(10):968-77. doi: 10.7326/0003-4819-134-10-200105150-00011. Erratum In: Ann Intern Med 2002 Jan 15;136(2):175.
- Volmink J, Matchaba P, Garner P. Directly observed therapy and treatment adherence. Lancet. 2000 Apr 15;355(9212):1345-50. doi: 10.1016/S0140-6736(00)02124-3. Erratum In: Lancet 2000 Jul 29;356(9227):434.
- Bangsberg DR, Mundy LM, Tulsky JP. Expanding directly observed therapy: tuberculosis to human immunodeficiency virus. Am J Med. 2001 Jun 1;110(8):664-6. doi: 10.1016/s0002-9343(01)00729-x. No abstract available.
- Kirkland LR, Fischl MA, Tashima KT, Paar D, Gensler T, Graham NM, Gao H, Rosenzweig JR, McClernon DR, Pittman G, Hessenthaler SM, Hernandez JE; NZTA4007 Study Team. Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment. Clin Infect Dis. 2002 Feb 15;34(4):511-8. doi: 10.1086/338400. Epub 2002 Jan 4.
- Gross R, Tierney C, Andrade A, Lalama C, Rosenkranz S, Eshleman SH, Flanigan T, Santana J, Salomon N, Reisler R, Wiggins I, Hogg E, Flexner C, Mildvan D; AIDS Clinical Trials Group A5073 Study Team. Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial. Arch Intern Med. 2009 Jul 13;169(13):1224-32. doi: 10.1001/archinternmed.2009.172.
- Flexner C, Tierney C, Gross R, Andrade A, Lalama C, Eshleman SH, Aberg J, Sanne I, Parsons T, Kashuba A, Rosenkranz SL, Kmack A, Ferguson E, Dehlinger M, Mildvan D; ACTG A5073 Study Team. Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial. Clin Infect Dis. 2010 Apr 1;50(7):1041-52. doi: 10.1086/651118.
研究記録日
主要日程の研究
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- A5073
- 10073 (レジストリ識別子:DAIDS ES)
- ACTG A5073
- AACTG A5073
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。